Meropenem Kabi

Meropenem, the active ingredient in Meropenem Kabi, is a carbapenem presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, ventilator‑associated pneumonia, severe sepsis, septic shock, and meningitis caused by susceptible organisms.

GNH USA supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious infections caused by susceptible bacteria.

- Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: eliminates pathogenic Gram‑negative and Gram‑positive organisms in complicated UTIs. - Hospital‑acquired pneumonia: achieves microbiological clearance in patients with nosocomial lung infections. - Ventilator‑associated pneumonia: resolves infection in intubated patients with ventilator‑related pneumonia. - Severe sepsis and septic shock: contributes to rapid bacterial load reduction in systemic infection. - Meningitis caused by susceptible organisms: penetrates the cerebrospinal fluid to treat bacterial meningitis.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Vomiting: occasional emesis. - Rash: transient skin erythema. - Elevated liver enzymes: mild transaminase increase. - Injection site pain: discomfort at the infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: antibiotic‑associated colitis. - Hemolytic anemia: rare immune‑mediated red cell destruction. - Thrombocytopenia: low platelet count, may increase bleeding risk. - Acute renal failure: rare but possible in susceptible individuals.

Use meropenem only under medical supervision, considering patient‑specific factors and infection severity.

- Renal function: adjust dose in patients with impaired kidney function. - CNS disorders: monitor for seizures, especially in patients with a history of epilepsy. - Hypersensitivity: avoid in individuals with known carbapenem or β‑lactam allergy. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Concomitant nephrotoxic drugs: monitor renal parameters when combined with other nephrotoxic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: risk of decreased plasma concentrations and loss of seizure control. - Probenecid: may increase meropenem levels, raising toxicity risk. - Aminoglycosides: combined nephrotoxicity; monitor renal function closely.

Moderate Interactions (Monitor Closely): - Diuretics: may affect electrolyte balance; watch for renal changes. - Anticoagulants (e.g., warfarin): possible alteration of INR; check coagulation parameters. - Other β‑lactam antibiotics: additive toxicity; assess need for combination therapy.